Mantle cell lymphoma: New treatments targeted to the biology

被引：6

作者：

Bertoni, F

Ghielmini, M

Cavalli, F

Cotter, FE

Zucca, E ^{[1
]}

机构：

[1] Osped San Giovanni Bellinzona, Div Med Oncol, Oncol Inst So Switzerland, CH-6500 Bellinzona, Switzerland

[2] Barts & London Queen Marys Sch Med & Dent, Dept Expt Hematol, London, England

来源：

CLINICAL LYMPHOMA | 2002年 / 3卷 / 02期

关键词：

monoclonal antibodies; rituximab; tositumomab; ibritumomab; apoptosis; CD20; proteasome inhibitors;

D O I：

10.3816/CLM.2002.n.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mantle cell lymphoma (MCL) represents a distinct lymphoma subtype. The prognosis of patients with MCL is the poorest among lymphoma patients and the response to conventional treatments is inadequate. New approaches targeted to the biology of MCL and the genetics underlying the disease are being studied. Monoclonal antibodies directed at molecules expressed on MCL cells are already used in the clinical setting. This article reviews the literature on these and other new possible treatment modalities.

引用

页码：90 / 96

页数：7

共 113 条

[31] Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma
Dreger, P
vonNeuhoff, N
Kuse, R
Sonnen, R
Glass, B
Uharek, L
Bartels, H
Loffler, H
Schmitz, N
[J]. ANNALS OF ONCOLOGY, 1997, 8 (04) : 401 - 403
[32] DREYLING M, 2001, ANN LYMPHOID MALIGNA, P61
[33] Controlling the mitochondrial gatekeeper for effective chemotherapy
Fennell, DA
Cotter, FE
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 52 - 60
[34] Ferreira CG, 2002, CLIN CANCER RES, V8, P2024
[35] FISHER R, 1999, MANTLE CELL LYMPHOMA, P325
[36] Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines
Flieger, D
Renoth, S
Beier, I
Sauerbruch, T
Schmidt-Wolf, I
[J]. CELLULAR IMMUNOLOGY, 2000, 204 (01) : 55 - 63
[37] Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
Flinn, IW
O'Donnell, PV
Goodrich, A
Vogelsang, G
Abrams, R
Noga, S
Marcellus, D
Borowitz, M
Jones, R
Ambinder, RF
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (06) : 628 - 632
[38] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
Foran, JM
Rohatiner, AZS
Cunningham, D
Popescu, RA
Solal-Celigny, P
Ghielmini, M
Coiffier, B
Johnson, PWM
Gisselbrecht, C
Reyes, F
Radford, JA
Bessell, EM
Souleau, B
Benzohra, A
Lister, TA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 317 - 324
[39] Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
Foran, JM
Cunningham, D
Coiffier, B
Solal-Celigny, P
Reyes, F
Ghielmini, M
Johnson, PWM
Gisselbrecht, C
Bradburn, M
Matthews, J
Lister, TA
[J]. ANNALS OF ONCOLOGY, 2000, 11 : 117 - 121
[40] Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
Ghetie, MA
Bright, H
Vitetta, ES
[J]. BLOOD, 2001, 97 (05) : 1392 - 1398

← 1 2 3 4 5 6 7 8 9 10 →